Prospective Study of 2-[ 18F]fluorodeoxyglucose positron emission tomography in the assessment of regional nodal spread of disease in patients with breast cancer: An Ontario Clinical Oncology Group study

Journal of Clinical Oncology

Volumn 30, Issue 12, 2012, Pages 1274-1279

  Pritchard, Kathleen I ^a,b,d,e   Julian, Jim A ^a,b   Holloway, Claire M B ^d,e   McCready, David ^e,f   Gulenchyn, Karen Yvonne ^c   George, Ralph ^e,g   Hodgson, Nicole ^b,c   Lovrics, Peter ^b,c   Perera, Francisco ⁱ   Elavathil, Leela ^b   O'Malley, Frances P ^e,g   Down, Nancy ^e,h   Bodurtha, Audley ^j   Shelley, Wendy ^k,l   Levine, Mark N ^a,b  

^a Ontario Clinical Oncology Group   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c HAMILTON HEALTH SCIENCES   (Canada)

^d DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f PRINCESS MARGARET HOSPITAL   (Canada)

^g ST MICHAEL'S HOSPITAL   (Canada)

^h NORTH YORK GENERAL HOSPITAL   (Canada)

ⁱ UNIVERSITY OF WESTERN ONTARIO   (Canada)

^j UNIVERSITY OF OTTAWA   (Canada)

^k Kingston Regional Cancer Centre   (Canada)

^l QUEEN S UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER STAGING; DISTANT METASTASIS; FEMALE; GOLD STANDARD; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TUMOR VOLUME; AXILLA; BREAST TUMOR; CANADA; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; LYMPH NODE; LYMPHADENECTOMY; METASTASIS; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; NEEDLE BIOPSY; PATHOLOGY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; STATISTICAL MODEL;

ADULT; AGED; AGED, 80 AND OVER; AXILLA; BIOPSY, NEEDLE; BREAST NEOPLASMS; CONFIDENCE INTERVALS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LOGISTIC MODELS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; ONTARIO; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY;

EID: 84862240855     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.1103     Document Type: Article

References (26)

1. McMasters KM, Giuliano AE, Ross MI, et al: Sentinel-lymph-node biopsy for breast cancer: Not yet the standard of care. N Engl J Med 339:990-995, 1998 (Pubitemid 28455104)
2. Cserni G, Amendoeira I, Apostolikas N, et al: Wells pathological work-up of sentinel lymph nodes in breast cancer: Review of current data to be considered for the formulation of guidelines. Eur J Cancer 39:1654-1667, 2003 (Pubitemid 36897601)
3. Warburg O, Wind F, Neglers E: On the Metabolism of Tumours in the Body: Metabolism of Tumors. London, United Kingdom, Constable, 1930, pp 254-270
4. Som P, Atkins H, Bandoypadjyay D: A fluorinated glucose analog, 2-fluoro-2deoxy-D-glucose (F18): Nontoxic tracer for rapid tumor detection. J Nucl Med 21:670-675, 1980 (Pubitemid 10034639)
5. Smith IC, Ogston KN: Staging of the axilla in breast cancer: Accurate in vivo assessment using positron emission tomography with 2-(fluorine-18) Fluro-2-deoxy-D-glucose. Ann Surg 228:220-227, 1998 (Pubitemid 30191718)
6. Greco M, Crippa F, Agresti R: Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: Clinical evaluation and alternative management. J Natl Cancer Inst 93:630-635, 2001 (Pubitemid 32409630)
7. Schirmeister H, Kuhn T, Guhlmann A: Fluorine-18 2-deoxy-2-fluoro-D- glucose PET in the preoperative stagin of breast cancer: Comparison with the standard staging procedures. Eur J Nucl Med 28:351-358, 2001
8. Yutani K, Shiba E, Kusuola H: Comparison of FDG-PET with MIBI-SPECT in the detection of breast cancer and axillary lymph node metastasis. J Comp Assist Tomog 24:274-280, 2000 (Pubitemid 32206208)
9. Adler L, Faulhaber P, Schnur K: Axillary lymph node metastases: Screening with (F-18) deoxy-2-fluoro-D-glucose (FDG) PET. Radiology 203:323-327, 1997 (Pubitemid 27176199)
10. van der Hoeven J, Hoekstra O, Comans E: Determinants of diagnostic performance of (F-18) fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer. Ann Surg 236:619-624, 2002 (Pubitemid 35246894)
11. Lovrics P, Chen W, Coates G, et al: A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer. Ann Surg Oncol 11:846-853, 2004
12. Wahl R, Siegel R, Coleman E, et al: A prospective multicentre study of axillary nodal staging by positron emission tomography in breast cancer: A report of the staging breast cancer with PET study group. J Clin Oncol 22:277-285, 2004 (Pubitemid 41095092)
13. Kelemen P, Lowe V, Phillips N: Positron emission tomography and sentinel lymph node dissection in breast cancer. Clin Breast Cancer 3:73-77, 2002 (Pubitemid 34546075)
14. Guller U, Nitzsche EU, Schirp U, et al: Selective axillary surgery in breast cancer patients based on positron emission tomography with F-fluoro-2- deoxy-D-glucose: Not yet! Breast Cancer Res Treat 71:171-173, 2002 (Pubitemid 34145374)
15. Young H, Baum R, Cremerius U, et al: Measurement of clinical and subclinical tumour response using 18F-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations-European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35:1773-1782, 1999 (Pubitemid 29512308)
16. McCready D, Yong W, Ng A, et al: Influence of the new AJCC breast cancer staging system on sentinel lymph node positivity and false-negative results. J Natl Cancer Inst 96:873-875, 2004 (Pubitemid 38807608)
17. Schwartz GF, Giuliano A, Veronesi U, et al: Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast. Human Pathol 33:529-589, 2002
18. Leisenring W, Pepe MS: Regression modelling of diagnostic likelihood ratios for the evaluation of medical diagnostic tests. Biometrics 54:444-452, 1998 (Pubitemid 28262469)
19. Veronesi U, De Cicco C, Galimberti E, et al: A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol 18:473-478, 2007 (Pubitemid 46359625)
20. Giuliano AE, Hunt KK, Ballman KV, et al: Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastases: A randomized clinical trial. JAMA 305:569-575, 2011
21. Carlson GW, Wood WC: Management of axillary lymph node metastases in breast cancer: Making progress. JAMA 305:606-607, 2011
22. Kumar R, Zhuang H, Schnall M, et al: FDG PET positive lymph nodes are highly predictive of metastasis in breast cancer. Nucl Med Commun 27:231-236, 2006 (Pubitemid 44391810)
23. Ikenaga N, Otomo N, Toyofuku A, et al: Standarized update values for breast carcinomas assessed by fluorodeoxyglucose-positron emission tomography correlate with prognostic factors. Am Surg 73:1151-1157, 2007 (Pubitemid 351396527)
24. Mustafa S, Marshall C, Griffiths PA, et al: 18 F-FDG dual-headed gamma camera PET in detection of axillary nodal disease in patients with large or locally advanced breast cancer: Possible alternative staging of axilla. Oncol Rep 18:1545-1549, 2007
25. Fuster D, Duch J, Paredes P, et al: Preoperative staging of large primary breast cancer with fluorodeoxyglucose positron emission tomography/ computed tomography compared with conventional imaging procedures. J Clin Oncol 26:4746-4751, 2008
26. Baslaim MM, Bakheet SM, Bakheet R, et al: 18-Fluorodeoxyglucose-positron emission tomography in inflammatory breast cancer. World J Surg 27:1099-1104, 2003 (Pubitemid 37259988)